Modulim to Present at LSI Emerging MedTech Summit

Irvine, CA—May 12, 2021—Modulim’s CEO, Charlie Huiner, will be presenting at this year’s LSI 2021 Emerging Medtech Summit in Dana Point, CA May 11th-13th 2021. Modulim’s FDA-cleared Clarifi® Imaging solution is well positioned to help healthcare providers manage patients with diabetes, kidney disease, and peripheral arterial disease who are at risk for lower limb complications. SFDI is a reimbursable under a proprietary CPT code. It is estimated that $237B is spent the US alone on diabetes care, of which $60B is directly related to reactive lower limb care. Modulim’s technology enables proactive management of at-risk limbs with rapid microvascular assessment at the point of care.

 

“We are excited to share the key milestones achieved by our team the past 18 months at LSI Medtech. Modulim is at a key inflection point and we look forward to connecting with capital partners at LSI,” said Charlie Huiner, CEO of Modulim. “The right partners can support growth as our team drives towards improving the lives of millions of patients dealing with chronic disease.”

 

Modulim will be presenting at this year’s LSI 2021 Emerging Medtech Summit in Dana Point, CA May 11th-13th 2021. LSI’s mission is to provide unique market insights so companies can deliver life changing technologies, faster.

 

About Modulim

 

Modulim is a privately held medical device company founded by the inventors of SFDI at the University of California Irvine with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Its mission is to deliver transformative optical solutions that help people live healthier, longer lives. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Clarifi Imaging System is an FDA cleared and CE Marked product. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK. Clarifi is a registered trademark of Modulated Imaging (dba Modulim).

 

Contacts

Gary Marston

VP Sales and Marketing

(949) 825-5075

gmarston@modulim.com